Pfizer Inc. (NYSE:PFE) Stake Lowered by Redwood Investment Management LLC

Redwood Investment Management LLC cut its holdings in Pfizer Inc. (NYSE:PFE) by 16.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 59,667 shares of the biopharmaceutical company’s stock after selling 11,876 shares during the period. Redwood Investment Management LLC’s holdings in Pfizer were worth $1,583,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Retirement Wealth Solutions LLC acquired a new position in shares of Pfizer during the fourth quarter valued at about $26,000. Rialto Wealth Management LLC bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $26,000. Clarity Asset Management Inc. acquired a new position in Pfizer in the fourth quarter valued at approximately $27,000. Kohmann Bosshard Financial Services LLC acquired a new position in Pfizer in the fourth quarter valued at approximately $28,000. Finally, Noble Wealth Management PBC acquired a new position in Pfizer in the fourth quarter valued at approximately $31,000. 68.36% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on PFE. The Goldman Sachs Group reiterated a “neutral” rating and issued a $25.00 target price (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Cantor Fitzgerald began coverage on Pfizer in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price target on the stock. Finally, UBS Group upped their target price on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $29.17.

Pfizer Trading Up 2.5%

Shares of PFE stock opened at $22.57 on Friday. The business’s fifty day moving average is $23.72 and its 200 day moving average is $25.40. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a market capitalization of $128.32 billion, a PE ratio of 16.01, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion for the quarter, compared to analysts’ expectations of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company’s revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period last year, the firm earned $0.82 earnings per share. On average, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be given a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.62%. Pfizer’s dividend payout ratio is currently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.